Screening and Prevention: Ovarian Cancer
1. Guidelines for Screening
General population 1-2% lifetime risk
Family history of breast and/or ovarian cancer
BRCA 1 and 2 mutation carriers – lifetime risk 60-85%
Hereditary non-polyposis colorectal cancer (HNPCC) – lifetime risk 7-12%
Prior diagnosis of breast, colorectal or uterine cancer
Age (post menopause)
Hormone replacement therapy
To date, no studies have shown that screening either high risk populations or the general population has an impact on mortality or morbidity of the disease
Women at very high risk (BRCA gene mutation carriers) may be screened with CA-125 and transvaginal ultrasonography at age 30-35 years or at age 5-10 years before the earliest age of onset of disease in the family. Prevention by removal of the ovaries after child-bearing is finished (see prevention section below)
No national organization or expert consensus panel recommends screening women at average risk. There is no evidence that any of the following can effectively screen the general population for ovarian cancer:
No randomized controlled clinical trial (RCT) of screening for ovarian cancer with mortality outcomes in the general population has been completed.
At least three RCTs are currently in progress:
UK Collaborative Trial of Ovarian Cancer Screening
NIH Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
European Randomized Trial of Ovarian Cancer Screening
New research has shown that symptom identification is important in the diagnosis of this disease. In women with abdominal bloating, increasing abdominal size, pelvic pain, abdominal pain, early satiety, difficulty eating, or urinary symptoms of new onset or greater than 12 times a month, ovarian cancer should be considered as a possibility.
2. Cancer Prevention
Identification of women at greatest genetic risk is the most effective prevention strategy.
Women at highest genetic risk – recommend risk reducing salpingo-oophorectomy between the ages of 35-50 and upon conclusion of childbearing or individualized based on age of earliest onset of ovarian cancer in the family.
Clinical trials are being conducted: